Related Experiment Video
Updated: Jun 22, 2026
07:48
An Orthotopic Bladder Cancer Model for Gene Delivery Studies
Published on: December 1, 2013
[Systemic chemotherapy for bladder cancer: news in 2009]
M Retz1, J E Gschwend, J Lehmann
1Urologische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universität, München, Deutschland. AUO@MeckEvidence.de
Der Urologe. Ausg. A
|June 27, 2009
Summary
This review covers chemotherapy for advanced urothelial carcinoma and bladder cancer, highlighting the shift from conventional treatments to targeted therapies. Molecular profiling may soon personalize treatment strategies for better outcomes.
Area of Science:
- Oncology
- Urothelial Carcinomas
- Bladder Cancer Therapeutics
Context:
- Review of systemic chemotherapy for advanced urothelial carcinoma.
- Analysis of adjuvant and neoadjuvant trials for locally advanced bladder cancer.
- Transition from conventional chemotherapy to targeted therapeutics in recent years.
Purpose:
- To summarize current treatment outcomes for advanced urothelial carcinoma.
- To evaluate data from bladder cancer neoadjuvant and adjuvant trials.
- To discuss the emerging role of molecular profiling in personalized cancer therapy.
Summary:
- Conventional systemic chemotherapy has been the standard for over two decades.
- Targeted therapeutics are increasingly utilized for urothelial cancer treatment.
- Molecular profiling is expected to guide individualized therapy in the future.
Impact:
- Provides a comprehensive overview of urothelial carcinoma treatment options.
- Highlights the evolving landscape of bladder cancer therapy.
- Suggests future directions for personalized oncology based on molecular profiling.
Related Concept Videos
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...